



## REFERENCES

- Aronoff, D.M. and Neilson, E.G. (2001) 'Antipyretics: mechanisms of action and clinical use in fever suppression', *The American Journal of Medicine*, 111(4), pp. 304–315. Available at: [https://doi.org/10.1016/S0002-9343\(01\)00834-8](https://doi.org/10.1016/S0002-9343(01)00834-8).
- Barrett, T.J. *et al.* (2021) 'Platelets contribute to disease severity in COVID-19', *Journal of Thrombosis and Haemostasis*, 19(12), pp. 3139–3153. doi:10.1111/jth.15534.
- Bergamaschi, G. *et al.* (2021) 'Anemia in patients with Covid-19: pathogenesis and clinical significance', *Clinical and Experimental Medicine*, 21(2), pp. 239–246. doi:10.1007/s10238-020-00679-4.
- Beyerstedt, S., Casaro, E.B. and Rangel, É.B. (2021) 'COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection', *European Journal of Clinical Microbiology & Infectious Diseases*, 40(5), pp. 905–919. doi:10.1007/s10096-020-04138-6.
- Caraceni, P., Tufoni, M. and Bonavita, M.E. (2013) 'Clinical use of albumin', *Blood Transfusion*, (11), pp. s18–s25. doi:10.2450/2013.005s.
- Centers for Disease Control and Prevention. 2021. Basics of COVID-19. [online] Available at: <<https://www.cdc.gov/coronavirus/2019-ncov/your-health/about-covid-19/basics-covid-19>> [Accessed 2 June 2022].
- Chaparro, C.M. and Suchdev, P.S. (2019) 'Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries', *Annals of the New York Academy of Sciences*, p. nyas.14092. doi:10.1111/nyas.14092.
- Chemokine Receptors', *Mediators of Inflammation*, 2020, pp. 1–7. doi:10.1155/2020/8198963.
- Cordon-Cardo, C. *et al.* (2020) 'COVID-19: Staging of a New Disease', *Cancer Cell*, 38(5), pp. 594–597. doi:10.1016/j.ccell.2020.10.006.
- da Rosa Mesquita, R. *et al.* (2021) 'Clinical manifestations of COVID-19 in the general population: systematic review', *Wiener klinische Wochenschrift*, 133(7–8), pp. 377–382. doi:10.1007/s00508-020-01760-4.
- Fajgenbaum, D.C. and June, C.H. (2020) 'Cytokine Storm', *New England Journal of Medicine*. Edited by D.L. Longo, 383(23), pp. 2255–2273. doi:10.1056/NEJMra2026131.
- Fountain, J.H. and Lappin, S.L. (2022) 'Physiology, Platelet', in *StatPearls*. Treasure Island (FL): StatPearls Publishing. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK470328/> (Accessed: 29 May 2022).
- Gabay, C. (2006) 'Interleukin-6 and chronic inflammation', *Arthritis Research & Therapy*, 8(Suppl 2), p. S3. doi:10.1186/ar1917.



- Gallo Marin, B. *et al.* (2021) 'Predictors of COVID -19 severity: A literature review', *Reviews in Medical Virology*, 31(1), pp. 1–10. doi:10.1002/rmv.2146. Guo, Y. *et al.* (2019) 'The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy', *Journal of Cancer*, 10(1), pp. 81–91. doi:10.7150/jca.27210.
- Hu, B. *et al.* (2021) 'Characteristics of SARS-CoV-2 and COVID-19', *Nature Reviews Microbiology*, 19(3), pp. 141–154. doi:10.1038/s41579-020-00459-7.
- Huang, C. *et al.* (2020) 'Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China', *The Lancet*, 395(10223), pp. 497–506. doi:10.1016/S0140-6736(20)30183-5.
- Huang, J. *et al.* (2020) 'Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity', *Journal of Medical Virology*, 92(10), pp. 2152–2158. doi:10.1002/jmv.26003. National Institutes of Health. 2021. Clinical Spectrum of SARS-CoV-2 Infection. [online] Available at:  
<<https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/#:~:text=Patients%20with%20COVID%2D19%20are,may%20experience%20rapid%20clinical%20deterioration>> [Accessed 2 June 2022].
- Larosa, D. and Orange, J. (2008) '1. Lymphocytes', *Journal of Allergy and Clinical Immunology*, 121(2), pp. S364–S369. doi:10.1016/j.jaci.2007.06.016.
- Lai, C.-C. *et al.* (2020) 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges', *International Journal of Antimicrobial Agents*, 55(3), p. 105924. doi:10.1016/j.ijantimicag.2020.105924.
- Liu, X., Zhang, R. and He, G. (2020) 'Hematological findings in coronavirus disease 2019: indications of progression of disease', *Annals of Hematology*, 99(7), pp. 1421–1428. doi:10.1007/s00277-020-04103-5.
- Lotfi, M., Hamblin, M.R. and Rezaei, N. (2020) 'COVID-19: Transmission, prevention, and potential therapeutic opportunities', *Clinica Chimica Acta*, 508, pp. 254–266. doi:10.1016/j.cca.2020.05.044.
- Marengo-Rowe, A.J. (2006) 'Structure-Function Relations of Human Hemoglobins', *Baylor University Medical Center Proceedings*, 19(3), pp. 239–245. doi:10.1080/08998280.2006.11928171.
- Mohammad, T., Choudhury, A., Habib, I., Asrani, P., Mathur, Y., & Umair, M. *et al.* (2021). Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach. *Frontiers In Cellular And Infection Microbiology*, 11. doi: 10.3389/fcimb.2021.765039



- Mustafa, M.I. *et al.* (2020) 'Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free
- Parasher, A. (2021) 'COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment', *Postgraduate Medical Journal*, 97(1147), pp. 312–320. doi:10.1136/postgradmedj-2020-138577.
- Santa Cruz, A. *et al.* (2021) 'Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia', *Frontiers in Immunology*, 12, p. 613422. doi:10.3389/fimmu.2021.613422.
- Satarker, S. and Nampoothiri, M. (2020) 'Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2', *Archives of Medical Research*, 51(6), pp. 482–491. doi:10.1016/j.arcmed.2020.05.012.
- Scheller, J. *et al.* (2011) 'The pro- and anti-inflammatory properties of the cytokine interleukin-6', *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1813(5), pp. 878–888. doi:10.1016/j.bbamcr.2011.01.034.
- Shereen, M.A. *et al.* (2020) 'COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses', *Journal of Advanced Research*, 24, pp. 91–98. doi:10.1016/j.jare.2020.03.005.
- Soeters, P.B., Wolfe, R.R. and Shenkin, A. (2019) 'Hypoalbuminemia: Pathogenesis and Clinical Significance', *Journal of Parenteral and Enteral Nutrition*, 43(2), pp. 181–193. doi:10.1002/jpen.1451.
- Tanaka, T., Narazaki, M. and Kishimoto, T. (2014) 'IL-6 in Inflammation, Immunity, and Disease', *Cold Spring Harbor Perspectives in Biology*, 6(10), pp. a016295–a016295. doi:10.1101/cshperspect.a016295.
- Tian, M. *et al.* (2021) 'The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score Is Associated With Poor Outcome of Acute Ischemic Stroke', *Frontiers in Neurology*, 11, p. 610318. doi:10.3389/fneur.2020.610318.
- Viana-Llamas, M.C. *et al.* (2021) 'Hypoalbuminemia on admission in COVID-19 infection: An early predictor of mortality and adverse events. A retrospective observational study', *Medicina Clínica*, 156(9), pp. 428–436. doi:10.1016/j.medcli.2020.12.018.
- Wang, M.-Y. *et al.* (2020) 'SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development', *Frontiers in Cellular and Infection Microbiology*, 10, p. 587269. doi:10.3389/fcimb.2020.587269.
- World Health Organization. 2022. WHO Coronavirus (COVID-19) Dashboard. [online] Available at: <<https://covid19.who.int>> [Accessed 2 June 2022].
- Wu, Y.-C., Chen, C.-S. and Chan, Y.-J. (2020) 'The outbreak of COVID-19: An overview', *Journal of the Chinese Medical Association*, 83(3), pp. 217–220. doi:10.1097/JCMA.0000000000000270.
- Xu, P., Zhou, Q. and Xu, J. (2020) 'Mechanism of thrombocytopenia in COVID-



- 19 patients', *Annals of Hematology*, 99(6), pp. 1205–1208. doi:10.1007/s00277-020-04019-0.
- Yuki, K., Fujiogi, M. and Koutsogiannaki, S. (2020) 'COVID-19 pathophysiology: A review', *Clinical Immunology*, 215,p.108427. doi:10.1016/j.clim.2020.108427.
- Zhang, C. *et al.* (2020) 'Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality', *International Journal of Antimicrobial Agents*, 55(5), p. 105954. doi:10.1016/j.ijantimicag.2020.105954.
- Zhang, H.-J. *et al.* (2021) 'Lymphocyte blood levels that remain low can predict the death of patients with COVID-19', *Medicine*, 100(28), p. e26503. doi:10.1097/MD.00000000000026503.
- Zuin, M. *et al.* (2021) 'Prognostic Role of Anemia in COVID-19 Patients: A Meta-Analysis', *Infectious Disease Reports*, 13(4), pp. 930–937. doi:10.3390/idr13040085.